![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Communiqué de presse : Mise en ligne du rapport financier semestriel 2024 de Sanofi Mise en ligne du rapport financier semestriel 2024 de Sanofi Paris, le 25 juillet 2024. Sanofi annonce...
Press Release: Online availability of Sanofi’s half-year financial report for 2024 Online availability of Sanofi’s half-year financial report for 2024 Paris, July 25, 2024. Sanofi announces that...
Online availability of Sanofi’s half-year financial report for 2024 Paris, July 25, 2024. Sanofi announces that its half-year financial report for the period ending June 30, 2024 is now available...
Communiqué de presse : Forte performance au deuxième trimestre soutenue par une croissance des ventes de 10% - Perspectives 2024 relevées Forte performance au deuxième trimestre...
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded Sanofi Q2: strong performance with 10% sales growth; 2024 guidance upgraded Paris, July 25, 2024 Q2...
Sanofi Q2: strong performance with 10% sales growth; 2024 guidance upgraded Paris, July 25, 2024 Q2 sales growth of 10.2% at CER and business EPS(1) of €1.73 Dupixent sales up 29.2% to €3,303...
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Juin 2024 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du...
Sanofi: Information concerning the total number of voting rights and shares – June 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8...
Communiqué de presse : Le NEJM publie les données de phase III de l’étude XTEND-Kids montrant qu’ALTUVIIIO a le potentiel de transformer la prise en charge thérapeutique des enfants atteints...
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A NEJM publishes ALTUVIIIO...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1226 | -0.511899791232 | 23.95 | 23.95 | 23.7735 | 2253 | 23.84218297 | SP |
4 | 0.0213 | 0.0894728661982 | 23.8061 | 23.9799 | 23.7735 | 2625 | 23.88810831 | SP |
12 | -0.9426 | -3.80540976988 | 24.77 | 24.77 | 23.7735 | 2393 | 23.88676651 | SP |
26 | -0.9426 | -3.80540976988 | 24.77 | 24.77 | 23.7735 | 2393 | 23.88676651 | SP |
52 | -0.9426 | -3.80540976988 | 24.77 | 24.77 | 23.7735 | 2393 | 23.88676651 | SP |
156 | -0.9426 | -3.80540976988 | 24.77 | 24.77 | 23.7735 | 2393 | 23.88676651 | SP |
260 | -0.9426 | -3.80540976988 | 24.77 | 24.77 | 23.7735 | 2393 | 23.88676651 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions